MIRA Pharmaceuticals (NASDAQ:MIRA) Upgraded to “Strong-Buy” at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of MIRA Pharmaceuticals (NASDAQ:MIRA) to a strong-buy rating in a research note published on Monday morning, Zacks.com reports.

A number of other research firms also recently commented on MIRA. Rodman & Renshaw assumed coverage on MIRA Pharmaceuticals in a research note on Monday. They issued a buy rating and a $17.00 price target for the company. Ascendiant Capital Markets began coverage on shares of MIRA Pharmaceuticals in a research report on Monday, August 5th. They issued a buy rating and a $11.00 target price for the company.

MIRA Pharmaceuticals Trading Down 8.5 %

Shares of MIRA opened at $1.19 on Monday. The stock has a market capitalization of $17.59 million and a PE ratio of -1.78. The firm’s 50 day moving average is $1.80 and its 200-day moving average is $1.20. MIRA Pharmaceuticals has a 12 month low of $0.51 and a 12 month high of $6.40.

MIRA Pharmaceuticals (NASDAQ:MIRA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Equities research analysts predict that MIRA Pharmaceuticals will post -0.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MIRA Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Cross Staff Investments Inc acquired a new stake in MIRA Pharmaceuticals in the first quarter valued at about $422,000. Virtu Financial LLC lifted its holdings in shares of MIRA Pharmaceuticals by 330.2% in the first quarter. Virtu Financial LLC now owns 63,055 shares of the company’s stock worth $69,000 after acquiring an additional 48,397 shares during the last quarter. Suncoast Equity Management acquired a new stake in shares of MIRA Pharmaceuticals in the 1st quarter valued at approximately $44,000. Finally, Praetorian Wealth Management Inc. bought a new stake in shares of MIRA Pharmaceuticals during the 1st quarter valued at approximately $30,000. Institutional investors own 35.16% of the company’s stock.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.